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Oxidative stress has been implicated in most non-communicable 
diseases: That is, metabolic syndrome (MetS), atherosclerosis, and cancer. 
Low-density lipoprotein cholesterol is rendered more atherogenic by 
oxidative modification [1], and many carcinogens create free oxygen 
radicals that damage DNA and other cellular structures, initiating 
and promoting tumor development [2]. Therefore, antioxidant agents 
have been extensively evaluated in the prevention of cardiovascular 
disease and cancer. Vitamin E has been shown to reduce atherosclerotic 
lesions in animals [3], smooth muscle cell proliferation [4], platelet 
adherence and aggregation [5]. Epidemiological data indicate an 
inverse association between cardiovascular or cancer risk and vitamin 
E intake from dietary sources and/or supplements [6]. However, most 
randomized controlled trials have failed to confirm a role for vitamin E 
supplementation in cardiovascular prevention [7-11]. Vitamin E had no 
significant effect on myocardial infarction, stroke, cardiovascular death, 
unstable angina, revascularization, and total mortality. Trials of cancer 
chemoprevention have also been disappointing [12,13].
Bilirubin has been recognized as a potent antioxidant. Bilirubin 
suppresses the oxidation of lipid in liposomes more than vitamin E, which 
is regarded as the best antioxidant of lipid peroxidation [14,15]. The 
water-soluble glutathione primarily protects water-soluble proteins, 
whereas the lipophilic bilirubin protects lipids from oxidation [16]. 
Serum bilirubin has been demonstrated to be a major contributor to 
the total antioxidant capacity in blood plasma [17] and proven to have 
anti-inflammatory properties [18]. Serum bilirubin was shown to be 
associated with cross-sectional MetS in Chinese children, adolescents, 
and adults [19,20] as well as Korean men and women [21,22]. Patients 
with Gilbert syndrome whose serum bilirubin levels are high had low 
levels of oxidative stress associated with enhancement of endothelium-
dependent vasodilation [23]. Serum bilirubin has been demonstrated 
to be negatively associated with cardiovascular disease [24-26], 
hemoglobin A1c [27], and albuminuria [28]. The author previously 
suggested that serum bilirubin might be a negative predictor of end-
stage kidney disease [29]. Others reported that serum bilirubin 
predicted MetS [30,31]. However, the author demonstrated that serum 
bilirubin cannot predict the development of MetS and suggested that 
a decreased serum bilirubin was not a cause of MetS but a marker of 
oxidative stress [32] which is closely related to inflammation [18] and 
endothelial dysfunction [23], both of which are thought to be underlying 
mechanisms of MetS [33]. Hence, further prospective studies are 
required to conclude whether a decrease in serum bilirubin is a risk 
factor for non-communicable disease such as MetS [34].
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